Novartis to shut down San Diego technical research and development facility

In an effort to “evolve” its global development organization, Novartis is set to exit a technical research and development site in San Diego, the Swiss pharma confirmed to Endpoints News.

The “phased exit” will affect about 100 staffers, with the company to leave the site by the second half of next year. According to a California WARN notice, 29 staffers will be laid off in San Diego with an effective date of September 6. The filing noted the permanent closure at 10210 Campus Point Drive.

The pharma will still have a “research presence” in San Diego — with a focus on indications like oncology, neuroscience and immunology — with “approximately 580 associates,” the spokesperson told Endpoints.

Novartis’ technical research and development team, or TRD, is delegated to progress assets through drug development and quality control. The company will now “consolidate” its TRD work in other US…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks